

PUBLICATION LIST

Original articles:

First- and senior author publications:

Aichelburg MC, Pinkowicz A, Holzer G, Radakovic S, Sator PG, Tanew A. (2021). Short- and long-term efficacy of fumaric acid esters or acitretin in combination with a 12-week course of PUVA in the treatment of palmoplantar pustulosis: results from a prospective randomized trial. *J Eur Acad Dermatol Venereol*. 35(3): e198-e200.

Aichelburg MC, Pinkowicz A, Schuster C, Volc-Platzer B, Tanew A. (2019). Patch granuloma annulare: Clinicopathological characteristics and response to phototherapy. *Br J Dermatol*. 181(1): 198-199.

Herout S, Mandorfer M, Breitenacker F, Reiberger T, Grabmeier-Pfistershammer K, Rieger A, **Aichelburg MC**. (2016). Impact of early initiation of antiretroviral therapy in patients with acute HIV infection in Vienna, Austria. *PLoS One*. 11(4): e0152910.

Aichelburg MC, Weseslindtner L, Mandorfer M, Strassl R, Rieger A, Reiberger T, Puchhammer-Stöckl E, Grabmeier-Pfistershammer K. (2015). Association of CMV-specific T cell mediated immunity with CMV DNAemia and development of CMV disease in HIV-1-infected individuals. *PLoS One*. 10(8): e0137096.

Aichelburg MC, Mandorfer M, Tittes J, Breitenacker F, Reiberger T, Rieger A, Kohrgruber N. (2014). The association of smoking with interferon- γ release assay and tuberculin skin test results in HIV-1-infected subjects. *Int J Tuberc Lung Dis*. 18(6): 709-16.

Aichelburg MC, Reiberger T, Breitenacker F, Mandorfer M, Makristathis A, Rieger A. (2014). Reversion and conversion of interferon-gamma release assay results in HIV-1-infected individuals. *J Infect Dis*. 209(5): 729-33.

Aichelburg MC, Tittes J, Breitenacker F, Reiberger T, Kohrgruber N, Rieger A. (2012). Prognostic value of indeterminate interferon- γ release assay results in HIV-1-infection. *J Clin Microbiol*. 50(8): 2767-9.

Aichelburg MC, Rieger A, Breitenacker F, Pfistershammer K, Tittes J, Eltz S, Aichelburg AC, Stingl G, Makristathis A, Kohrgruber N. (2009). Detection and prediction of active tuberculosis disease by a whole-blood interferon- γ release assay in HIV-1-infected individuals. *Clin Infect Dis*. 48(7): 954-62.

Co-author publications:

Perschy L, Anzengruber F, Rappersberger K, Itzlinger-Monshi B, **Aichelburg MC**, Graf V, Hafner J, Vujic I. (2022). Apremilast in oral lichen planus – a multicentric, retrospective study. *J Dtsch Dermatol Ges*. 20(3): 343-348.

Reitermaier R, Skoll M, Touzeau-Roemer V, **Aichelburg MC**, Elbe-Bürger A, Bauer W, Rieger A, Schuster C. (2021). Frequency of envoplakin and type VII collagen autoantibodies and co-occurrence with other skin-specific autoantibodies in HIV-infected patients and uninfected controls. *Acta Derm Venereol*. Online ahead of print.

Gupta RK, Calderwood CJ, Yavlinsky A, Krutikov M, Quartagno M, **Aichelburg MC**, Altet N, Diel R, Dobler CC, Dominguez J, Doyle JS, Erkens C, Geis S, Haldar P, Hauri AM, Hermansen T, Johnston JC, Lange C, Lange B, van Leth F, Muñoz L, Roder C, Romanowski K, Roth D, Sester M, Sloot R, Sotgiu G, Woltmann G, Yoshiyama T, Zellweger JP, Zenner D, Aldridge RW, Copas A, Rangaka MX, Lipman M, Noursadeghi M, Abubakar I. (2020). Discovery and validation of a personalized risk predictor for incident tuberculosis in low transmission settings. *Nat Med*. 26(12): 1941-1949.

Touzeau-Roemer V, Skoll M, Tajpara P, Kienzl P, Wesinger A, Saluzzo S, Bauer M, **Aichelburg MC**, Bangert C, Bauer W, Stingl G, Rieger A, Grabmeier-Pfistershammer K, Schuster C. (2019). Prevalence of skin-specific autoantibodies in HIV-infected patients and uninfected controls. *Acta Derm Venereol.* 99(11): 978-983.

Chromy D, Mandorfer M, Bucsecs T, Schwabl P, Scheiner B, Schmidbauer C, **Aichelburg MC**, Ferenci P, Trauner M, Peck-Radosavljevic M, Reiberger T. (2019). High efficacy of interferon-free therapy for acute hepatitis C in HIV-positive patients. *United European Gastroenterol J.* 7(4): 507-516.

Schuster C, Mayer FJ, Wohlfahrt C, Marculescu R, Skoll M, Strassl R, Pavo N, Popow-Kraupp T, Hülsmann M, Bauer M, **Aichelburg MC**, Rieger A, Goliash G. (2018). Acute HIV infection results in subclinical inflammatory cardiomyopathy. *J Infect Dis.* 218(3): 466-470.

Chromy D, Schwabl P, Bucsecs T, Scheiner B, Strassl R, Mayer F, **Aichelburg MC**, Grabmeier-Pfistershammer K, Trauner M, Peck-Radosavljevic M, Reiberger T, Mandorfer M. (2018). Non-invasive liver fibrosis assessment and HCV treatment initiation within a systematic screening program in HIV/HCV coinfecting patients. *Wien Klin Wochenschr.* 130(3-4): 105-114.

Bauer WM, **Aichelburg MC**, Griss J, Skrabs C, Simonitsch-Klupp I, Schiefer AI, Kittler H, Jäger U, Zeyda M, Knobler R, Stingl G. (2017). Molecular classification of tumor cells in a patient with intravascular large B-cell lymphoma. *Br J Dermatol.* 178(1): 215-221.

Steiner S, Bucsecs T, Schwabl P, Mandorfer M, Scheiner B, **Aichelburg MC**, Grabmeier-Pfistershammer K, Ferenci P, Trauner M, Peck-Radosavljevic M, Reiberger T. (2017). Progress in eradication of HCV in HIV positive patients with significant liver fibrosis in Vienna. *Wien Klin Wochenschr.* 129(15-16): 517-526.

Schuster C, Binder C, Strassl R, **Aichelburg MC**, Blackwell E, Pavo N, Ramharter M, Hülsmann M, Grabmeier-Pfistershammer K, Rieger A, Goliash G. (2017). Impact of HIV infection and antiretroviral treatment on N-terminal prohormone of brain natriuretic peptide as surrogate of myocardial function. *AIDS.* 31(3): 395-400.

Scheiner B, Schwabl P, Steiner S, Bucsecs T, Chromy D, **Aichelburg MC**, Grabmeier-Pfistershammer K, Trauner M, Peck-Radosavljevic M, Reiberger T, Mandorfer M. (2016). Interferon-free regimens improve health-related quality of life and fatigue in HIV/HCV-coinfecting patients with advanced liver disease: A retrospective study. *Medicine (Baltimore).* 95(27): e4061.

Mandorfer M, Schwabl P, Steiner S, Scheiner B, Chromy D, Bucsecs T, Stättermayer AF, **Aichelburg MC**, Grabmeier-Pfistershammer K, Trauner M, Reiberger T, Peck-Radosavljevic M. (2016). Interferon-free treatment with sofosbuvir/daclatasvir achieves sustained virologic response in 100% of HIV/HCV-coinfecting patients with advanced liver disease. *AIDS.* 30(7): 1039-47.

Mandorfer M, Steiner S, Schwabl P, Payer BA, **Aichelburg MC**, Grabmeier-Pfistershammer K, Trauner M, Reiberger T, Peck-Radosavljevic M. (2015). Treatment intensification with boceprevir in HIV-positive patients with acute HCV-genotype 1 infection at high risk for treatment failure. *Wien Klin Wochenschr.* 128(11-12): 414-20.

Scheiner B, Mandorfer M, Schwabl P, Payer BA, Bucsecs T, Bota S, **Aichelburg MC**, Grabmeier-Pfistershammer K, Stättermayer A, Ferenci P, Trauner M, Peck-Radosavljevic M, Reiberger T. (2015). The impact of PNPLA3 rs738409 SNP on liver fibrosis progression, portal hypertension and hepatic steatosis in HIV/HCV coinfection. *PLoS One.* 10(11): e0143429.

Mandorfer M, Steiner S, Schwabl P, Payer BA, **Aichelburg MC**, Lang G, Grabmeier-Pfistershammer K, Trauner M, Peck-Radosavljevic M, Reiberger T. (2015). Response-guided Boceprevir-based triple-therapy in HIV/HCV-coinfecting patients: The HIVCOBOC-RGT Study. *J Infect Dis.* 211(5): 729-35.

Mandorfer M, Payer BA, Schwabl P, Steiner S, Ferlitsch A, **Aichelburg MC**, Stättermayer AF, Ferenci P, Obermayer-Pietsch B, Grabmeier-Pfistershammer K, Trauner M, Peck-Radosavljevic M, Reiberger T; Vienna HIV & Liver Study Group. (2015). Revisiting liver disease progression in HIV/HCV-coinfecting

patients: The influence of vitamin D, insulin resistance, immune status, IL28B and PNPLA3. *Liver Int.* 35(3): 876-85.

Mandorfer M, Payer BA, Niederecker A, Lang G, **Aichelburg MC**, Strassl R, Boesecke C, Rieger A, Trauner M, Peck-Radosavljevic M, Reiberger T. (2014). Therapeutic Potential of and Treatment with Boceprevir/Telaprevir-Based Triple-Therapy in HIV/Chronic Hepatitis C Co-Infected Patients in a Real-World Setting. *AIDS Patient Care STDS.* 28(5): 221-7.

Mandorfer M, Reiberger T, Payer BA, Breitenecker F, **Aichelburg MC**, Obermayer-Pietsch B, Rieger A, Puoti M, Zangerle R, Trauner M, Peck-Radosavljevic M. (2014). Revisiting predictors of virologic response to PEGIFN + RBV therapy in HIV-/HCV-coinfected patients: the role of metabolic factors and elevated GGT levels. *J Viral Hepat.* 21(1): 33-41.

Mandorfer M, Payer BA, Scheiner B, Breitenecker F, **Aichelburg MC**, Grabmeier-Pfistershammer K, Rieger A, Trauner M, Peck-Radosavljevic M, Reiberger T. (2014). Health-related quality of life and severity of fatigue in HIV/HCV co-infected patients before, during, and after antiviral therapy with pegylated interferon plus ribavirin. *Liver Int.* 34(1): 69-77.

Tittes J, **Aichelburg MC**, Antoniewicz L, Geusau A. (2013). Enhanced therapy for primary and secondary syphilis: a longitudinal retrospective analysis of cure rates and associated factors. *Int J STD AIDS.* 24(9): 703-11.

Mandorfer M, Reiberger T, Payer BA, Ferlitsch A, Breitenecker F, **Aichelburg MC**, Obermayer-Pietsch B, Rieger A, Trauner M, Peck-Radosavljevic M; Vienna HIV & Liver Study Group). (2013). Low vitamin D levels are associated with impaired virologic response to PEGIFN+RBV therapy in HIV-hepatitis C virus coinfecting patients. *AIDS.* 27(2): 227-32.

Reiberger T, Payer BA, Ferlitsch A, Sieghart W, Breitenecker F, **Aichelburg MC**, Schmied B, Rieger A, Trauner M, Peck-Radosavljevic M (Vienna Hepatic Hemodynamic Lab and Vienna HIV & Liver Study Group). (2012). A prospective evaluation of pulmonary, systemic and hepatic hemodynamics in HIV-HCV-coinfecting patients before and after antiviral therapy with pegylated interferon and ribavirin. *Antivir Ther.* 17(7): 1327-34.

Payer BA, Reiberger T, Breitenecker F, **Aichelburg MC**, Schuster C, Heil PM, Scherzer TM, Ferenci P, Rieger A, Peck-Radosavljevic M; Vienna HIV & Liver Study Group. (2012). The risk of infections in HIV-HCV coinfecting patients during antiviral therapy with pegIFN+RBV. *J Infect.* 65(2): 142-9.

Mahomed H, **Aichelburg MC**, Diel R, Sbarbaro JA. (2010). Longitudinal studies PPV and NPV of IGRAs. *Int J Tuberc Lung Dis.* 14(6):48-54.

Case reports:

Volc S, Maier L, Gritsch A, **Aichelburg MC**, Volc-Platzer B. (2020). Successful treatment of Netherton syndrome with ustekinumab in a 15-year old girl. *Br J Derm.* 183(1): 165-167.

Schuster C, **Aichelburg MC**, Rieger A, Grabmeier-Pfistershammer K. (2014). Successful and rapid treatment of two patients with bacillary angiomatosis with azithromycin. *Aperito J Dermatol.* 2(1): 106-110.

Aichelburg MC, Loewe R, Schicher N, Sator PG, Karlhofer F, Stingl G, Jalili A. (2012). Successful treatment of poststreptococcal scleroedema adoltorum Buschke with intravenous immunoglobulins. *Arch Derm.* 148(10): 1126-8.

Aichelburg MC, Rieger A. (2012). Primary syphilitic chancre on the upper arm in an HIV-1-infected patient. *Int J STD AIDS.* 23(8): 597-8.

Letters:

Aichelburg MC, Tanew A. (2019). Secukinumab without the initial loading dose in the treatment of plaque-type psoriasis – a simplified dosing regimen at the expense of efficacy? *Br J Derm.* 182(1): 18-19.

Aichelburg MC. (2015). Reply to Schepisi et al. *J Infect Dis.* 211(11): 1854.

Abstracts (presenting author):

Aichelburg MC, Pinkowicz A, Schuster C, Volc-Platzer B, Tanew A. (2018). Patch granuloma annulare: Clinicopathological characteristics and response to phototherapy. Annual Conference of the Austrian Society of Dermatology and Venerology (OEGDV), Innsbruck, Austria, 29 November-1 December 2018. Austrian Society of Dermatology and Venerology, 2018: [abstract P77]

Aichelburg MC, Schuster C, Pinkowicz A, Volc-Platzer B, Tanew A. (2018). Treatment of patch granuloma annulare with phototherapy: results of a case series. 27th Congress of the European Academy of Dermatology and Venereology, Paris, France, 12-16 September 2018.

Aichelburg MC, Reiberger T, Breitenecker F, Makristathis A, Rieger A. (2013). Serial testing with an interferon-gamma release assay in HIV-1-infected individuals. STI&AIDS World Congress, Vienna, Austria, 14-17 July 2013. Sex Trans Infect; 89 (S1): [abstract P2.045]

Aichelburg MC, Reiberger T, Breitenecker F, Makristathis A, Rieger A. (2013). Reversion and conversion of interferon-gamma release assay results in HIV-1-infected individuals. 6th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention, Kuala Lumpur, Malaysia, 30 June-3 July 2013. International AIDS Society, 2011: [abstract WEPE466]

Aichelburg MC, Breitenecker F, Reiberger T, Makristathis A, Rieger A. (2012). Reversion and conversion of interferon-gamma release assay results in HIV-1-infected individuals. 52th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, USA, 9-12 September 2012. American Society of Microbiology, 2012: [abstract H-1918]

Aichelburg MC, Tittes J, Breitenecker F, Kohrgruber N, Rieger A. (2011). Indeterminate results of an Interferon-gamma release assay indicate an increased risk for progression to AIDS irrespective of CD4+ T cell count. 5th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention, Rome, Italy, 17-20 July 2011. International AIDS Society, 2011: [abstract TUPE158]

Aichelburg MC, Schlag M, Breitenecker F, Rieger A. (2011). Initiation of antiretroviral therapy according to the current EACS guidelines: Results of a clinical audit. 5th German-Austrian AIDS Congress, Hannover, Germany, 15-18 June 2011. Eur J Med Res; 12 (Suppl II): 77

Aichelburg MC, Schlag M, Rieger A. (2010). Eligibility for the initiation of HIV treatment in the context of the updated EACS guidelines: Results of a clinical audit. 10th International Congress on Drug Therapy in HIV Infection, Glasgow, UK, 07-11 November 2010. International AIDS Society, 2010: [abstract P22]

Aichelburg MC, Tittes J, Aichelburg AC, Stingl G, Rieger A, Kohrgruber N. (2010). Comparison of t-cell based interferon- γ release assay and tuberculin skin test results for the prediction of active tuberculosis disease in HIV-1 infection. 18th International AIDS Conference, Vienna, Austria, 18-23 July 2010. International AIDS Society, 2010: [abstract MOPE0129]

Aichelburg MC, Tittes J, Breitenecker F, Pfistershammer K, Aichelburg AC, Stingl G, Rieger A, Kohrgruber N. (2009). Comparison of whole-blood interferon-gamma release assay and tuberculin skin test results for the prediction of active tuberculosis disease in HIV-infected individuals. 19th Annual European Respiratory Society (ERS) Congress, Vienna, Austria, 12-16 September 2009. European Respiratory Society, 2009: 304

Aichelburg MC, Rieger A, Kohrgruber N. (2009). Indeterminate results of the QuantiFERON-TB Gold In-Tube assay indicate an increased risk for disease progression in HIV-1-infected individuals. 5th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention, Cape Town, South Africa, 19-22 July 2009. International AIDS Society, 2009: [abstract TUBEP 131]

Aichelburg MC, Tittes J, Breitenecker F, Pfistershammer K, Aichelburg AC, Stingl G, Rieger A, Kohrgruber N. (2009). Predictive value of a whole-blood interferon-gamma release assay and tuberculin skin test in HIV-1-infected individuals. 5th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention, Cape Town, South Africa, 19-22 July 2009. International AIDS Society, 2009: [abstract TUBEP124]

Aichelburg MC, Rieger A, Breitenecker F, Pfistershammer K, Tittes J, Eltz S, Aichelburg AC, Stingl G, Makristathis A, Kohrgruber N. (2008). Detection and prediction of active *Mycobacterium tuberculosis* infection by a whole-blood interferon-gamma release assay in HIV-1-infected individuals. 19th Austrian AIDS Congress, Vienna, Austria, 3-4 October 2008. Austrian AIDS Society, 2008: 42

Aichelburg MC, Makristathis A, Breitenecker F, Eltz S, Aichelburg AC, Rieger A, Kohrgruber N. (2007). Correlation of clinical data with reactivity in the interferon- γ release assay for tuberculosis antigens in HIV-infected patients. 4th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention, Sydney, Australia, 22-25 July 2007. International AIDS Society, 2007: 54 [abstract MOPEB021]

Aichelburg MC, Makristathis A, Breitenecker F, Eltz S, Rieger A, Kohrgruber N. (2007). *M. tuberculosis* specific interferon- γ release in HIV-infected patients. 3rd German-Austrian AIDS Congress, Frankfurt am Main, Germany, 27-30 June 2007. Eur J Med Res 12 (Suppl II): 77

Abstracts (co-author):

Chromy D, Mandorfer M, Bauer D, Schwabl P, Simbrunner B, Schmidbauer C, Bucsecs T, Seeland B, **Aichelburg MC**, Grabmeier-Pfistershammer K, Rieger A, Peck M, Reiberger T. (2019). Success of unrestricted DAA therapy is limited by HCV reinfections and loss to follow-up in HIV-positive patients. 17th European AIDS Conference, Basel, Switzerland, 6-9 November 2019. HIV Med 20(S9): 292.

Schuster C, Mayer FJ, Wohlfahrt C, Marculescu R, Skoll M, Strassl R, **Aichelburg MC**, Pavo N, Popow-Kraupp T, Hülsmann M, Bauer M, Rieger A, Goliash G. (2018). Acute HIV infection results in subclinical and reversible inflammatory cardiomyopathy. Conference on Retroviruses and Opportunistic Infections (CROI), Boston, USA, 4-7 March 2018. [abstract 699]

Scheiner B, Schwabl P, Mandorfer M, Steiner S, Chromy D, Bucsecs T, Payer BA, **Aichelburg MC**, Rieger A, Grabmeier-Pfistershammer K, Trauner M, Peck-Radosavljevic M, Reiberger T. (2015). IFN-free DAA regimens improve on-treatment quality of life in patients with HIV/HCV coinfection in contrast to previously used PEGIFN/RBV regimens. 66th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), San Francisco, USA, 13-17 November 2015. Hepatology; 62 (Suppl. 1) 805A: 1204

Mandorfer M, Chromy D, Strassl R, Schwabl P, Steiner S, Scheiner B, **Aichelburg MC**, Grabmeier-Pfistershammer K, Rieger A, Trauner M, Peck-Radosavljevic M, Reiberger T. (2015). Rates of liver fibrosis assessment and treatment initiation with IFN-free regimens within a screening program for advanced liver fibrosis among HIV/HCV-coinfected patients. 66th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), San Francisco, USA, 13-17 November 2015. Hepatology; 62 (Suppl. 1) 488A: 561

Scheiner B, Mandorfer M, Schwabl P, Payer BA, **Aichelburg MC**, Grabmeier-Pfistershammer K, Stättermayer A, Ferenci P, Trauner M, Peck-Radosavljevic M, Reiberger T. (2015). The presence of a PNPLA3 (rs738409) single nucleotide polymorphism (SNP) is not associated with increased risk for fibrosis, portal hypertension, and hepatic steatosis in HIV/HCV-coinfected patients. 48th Annual Meeting of the OEGGH, Salzburg, Austria, 18-20 June 2015. Z Gastroenterol; 53 (5) 504: P65

Mandorfer M, Steiner S, Schwabl P, **Aichelburg MC**, Grabmeier-Pfistershammer K, Rieger A, Trauner M, Reiberger T, Peck-Radosavljevic M. (2015). Interferon and ribavirin-free therapy with sofosbuvir and daclatasvir in a real-life cohort of difficult-to-treat HIV/HCV-coinfected patients. 48th Annual Meeting 2015 of the OEGGH, Salzburg, Austria, 18-20 June 2015. Z Gastroenterol; 53 (5) 502: P59

Mandorfer M, Steiner S, Schwabl P, **Aichelburg MC**, Grabmeier-Pfistershammer K, Rieger A, Trauner M, Reiberger T, Peck-Radosavljevic M. (2015). Interferon and ribavirin-free therapy with sofosbuvir and daclatasvir in a real-life cohort of difficult to treat HIV/HCV-coinfected patients with and without portal hypertension. 50th Annual Meeting of the European Association for the Study of the Liver (EASL), Vienna, Austria, 22-26 April 2015. Journal of Hepatology; 62 S673: P0884

Scheiner B, Mandorfer M, Schwabl P, Payer BA, **Aichelburg MC**, Grabmeier-Pfistershammer K, Stättermayer AF, Ferenci P, Trauner M, Peck-Radosavljevic M, Reiberger T. (2015). The presence of a PNPLA3 (RS738409) single nucleotide polymorphism (SNP) is not associated with increased risk for fibrosis, portal hypertension, and hepatic steatosis in HIV/HCV-coinfected patients. 50th Annual Meeting of the European Association for the Study of the Liver (EASL), Vienna, Austria, 22-26 April 2015. *Journal of Hepatology*; 62 S593: P0717

Bauer W, **Aichelburg MC**, Griss J, Kittler H, Skrabs K, Simonitsch-Klupp I, Schiefer A, Jäger U, Streubel B, Stingl G. (2014). Molecular Analysis of Intravascular Large B-Cell Lymphoma. Inflammatory Skin Disease Summit 2014, Vienna, Austria, 19-21 November 2014. [abstract P077]

Mandorfer M, Steiner S, Schwabl P, Payer BA, **Aichelburg MC**, Lang G, Grabmeier-Pfistershammer K, Trauner M, Reiberger T, Peck-Radosavljevic M. (2014). Add-on of Boceprevir in HIV-positive Patients with Genotype 1 Acute Hepatitis C at high Risk for Treatment Failure. 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), Boston, USA, 7-11 November 2014. *Hepatology*; 60 (Suppl) 160A: 1452

Mandorfer M, Steiner S, Schwabl P, Payer BA, **Aichelburg MC**, Lang G, Grabmeier-Pfistershammer K, Trauner M, Reiberger T, Peck-Radosavljevic M. (2014). Response-guided Boceprevir-based Triple Therapy in HIV/HCV-coinfected Patients: The HIVCOBOC-RGT Study. 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), Boston, USA, 7-11 November 2014. *Hepatology*; 60 (Suppl) 163A: 1497

Steiner S, Payer BA, Mandorfer M, Niederecker A, Lang G, **Aichelburg MC**, Strassl R, Boesecke C, Rieger A, Trauner M, Peck-Radosavljevic M, Reiberger T. (2014). Therapeutic potential of and treatment with boceprevir/telaprevir-based triple-therapy in HIV/chronic hepatitis C coinfecting patients in a real-world setting. 47th Annual Meeting 2014 of the Österreichische Gesellschaft für Gastroenterologie und Hepatologie (OEGGH), Villach, Austria, 12-14 June 2014. *Z Gastroenterol*; 52(5): P56

Mandorfer M, Payer BA, Schwabl P, Steiner S, Ferlitsch A, **Aichelburg MC**, Stättermayer AF, Ferenci P, Obermayer-Pietsch B, Grabmeier-Pfistershammer K, Trauner M, Peck-Radosavljevic M, Reiberger T. (2014). Revisiting Liver Disease Progression in HIV/HCV-coinfected Patients: The Influence of Vitamin D, Insulin resistance, Immune status, IL28B and PNPLA3. 47th Annual Meeting 2014 of the Österreichische Gesellschaft für Gastroenterologie und Hepatologie (OEGGH), Villach, Austria, 12-14 June 2014. *Z Gastroenterol*; 52(5): P47

Scheiner B, Mandorfer M, Payer BA, Breitencker F, **Aichelburg MC**, Grabmeier-Pfistershammer K, Rieger A, Trauner M, Peck-Radosavljevic M, Reiberger T. (2014). Gesundheitsbezogene Lebensqualität bei HIV-HCV-Koinfektion vor, während und nach antiviraler Therapie mit PEGIFN + RBV. 47th Annual Meeting 2014 of the Österreichische Gesellschaft für Gastroenterologie und Hepatologie (OEGGH), Villach, Austria, 12-14 June 2014. *Z Gastroenterol*; 52(5): P40

Mandorfer M, Payer BA, Steiner S, Ferlitsch A, **Aichelburg MC**, Stättermayer AF, Ferenci P, Obermayer-Pietsch B, Grabmeier-Pfistershammer K, Trauner M, Peck-Radosavljevic M, Reiberger T. (2014). Revisiting liver fibrosis progression in HIV/HCV-coinfected patients: the influence of vitamin D, insulin resistance, immune status, IL28B, and PNPLA3. 49th Annual Meeting of the European Association for the Study of the Liver (EASL), London, United Kingdom, 9-13 April 2014. *Journal of Hepatology*; (Suppl1)

Mandorfer M, Reiberger T, Payer BA, **Aichelburg MC**, Breitencker F, Lang G, Rieger A, Trauner M, Peck-Radosavljevic M. (2013). Potential of and first experience with the use of triple-therapy in HIV/hepatitis C virus coinfecting patients. 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), Washington DC, USA, 1-5 November 2013. *Hepatology*; [abstract 2261]

Mandorfer M, Payer BA, Reiberger T, Pfisterer N, **Aichelburg MC**, Rieger A, Trauner M, Peck-

Radosavljevic M, Vienna HIV & Liver Study Group. (2013). Prevalence of and risk factors for combined cART associated drug-induced liver injury in HIV/HBV coinfecting, HIV/HCV coinfecting, and HIV mono-infected patients. 48th Annual Meeting of the European Association for the Study of the Liver (EASL), Amsterdam, Netherlands, 24-28 April 2013. Journal of Hepatology; 58 (Suppl I), S147: A354

Mandorfer M, Reiberger T, Payer BA, Ferlitsch A, Breitenecker F, **Aichelburg MC**, Rieger A, Trauner M, Peck-Radosavljevic M, Vienna HIV & Liver Study Group. (2013). The influence of portal pressure and the discordance of absolute CD4+ count and CD4+ percentage in HIV/HCV coinfecting patients. 48th Annual Meeting of the European Association for the Study of the Liver (EASL), Amsterdam, Netherlands, 24-28 April 2013. Journal of Hepatology; 58 (Suppl I), S194: A475

Mandorfer M, Reiberger T, Payer BA, Breitenecker F, **Aichelburg MC**, Obermayer-Pietsch B, Rieger A, Puoti M, Zangerle R, Trauner M, Peck-Radosavljevic M, Vienna HIV & Liver Study Group. (2013). Revisiting predictors of virologic response to PEGIFN+RBV therapy in HIV/HCV coinfecting patients: the role of metabolic factors and elevated GGT levels. 48th Annual Meeting of the European Association for the Study of the Liver (EASL), Amsterdam, Netherlands, 24-28 April 2013. Journal of Hepatology; 58 (Suppl I), S352: A860

Payer BA, Reiberger T, Stift J, **Aichelburg MC**, Breitenecker F, Ferenci P, Rieger A, Peck-Radosavljevic M. (2012). PNPLA3 polymorphism is not associated with hepatic steatosis and fibrosis progression in HIV/HCV coinfecting patients. 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), Boston, USA, 9-13 November 2012. [abstract 1744]

Mandorfer M, Reiberger T, Payer BA, Ferlitsch A, Breitenecker F, **Aichelburg MC**, Obermayer-Pietsch B, Rieger A, Peck-Radosavljevic M. (2012). Low vitamin D serum levels are associated with liver fibrosis and impaired virologic response to antiviral therapy with PEGIFN+RBV in HIV/HCV coinfecting patients. 47th Annual Meeting of the European Association for the Study of the Liver (EASL), Barcelona, Spain, 18-22 April 2012. Journal of Hepatology; 56 (Suppl II), S353: A907

Payer BA, Reiberger T, Stift J, **Aichelburg MC**, Breitenecker F, Rieger A, Peck-Radosavljevic M. (2012). Influence of PNPLA3 SNP on hepatic steatosis and fibrosis progression in HIV-HCV coinfecting patients. 47th Annual Meeting of the European Association for the Study of the Liver (EASL), Barcelona, Spain, 18-22 April 2012. Journal of Hepatology; 56 (Suppl II), S356: A915

Jalili A, **Aichelburg MC**, Loewe R, Schicher N, Stingl G, Tanew A. (2011). Successful treatment of scleroedema adutorum Buschke (SAB, a rare post-streptococcal complication) with intravenous immunoglobulin (IVIg). 38th Annual Meeting of the Society for Dermatological Research, Tuebingen, Germany, 17-19 February 2011. P 158

Invited Presentations:

Aichelburg MC. Acute HIV infection-state of the art. 3rd EACS Young Investigators Conference (YING), virtual, 11-12 December 2020

Aichelburg MC. Scabies. 10th Kinder-Haut-Tag, Vienna, Austria, 18 October 2019

Aichelburg MC. Case-based update on sexually transmitted diseases. 2nd EACS Young Investigators Conference (YING), Brussels, Belgium, 13-14 April 2018

Aichelburg MC. We can make a difference-Psoriasis case reports in routine clinical practice. Vienna, Austria, 16 March 2018

Aichelburg MC. Measles update, Sozialmedizinisches Zentrum Ost, Donauespital, Vienna, Austria, 19 September 2017

Aichelburg MC. Address the health checks in medical care. 1st EACS Young Investigators Conference (YING), Brussels, Belgium, 16 December 2016

Aichelburg MC. Hepatitis C and the changing landscape. 14th European AIDS Conference, Brussels, Belgium, 16-19 October 2013

Aichelburg MC. Predictive value of IGRAs in HIV-infected individuals. 2nd Global Symposium on IGRAs, Dubrovnik, Croatia, 30 May-1 June 2009

Aichelburg MC. QuantiFERON-screening in HIV-infected patients. 50th Conference of the German Society for Pneumology and Ventilation, Mannheim, Germany, 18-21 March 2009. German Society for Pneumology and Ventilation, 2008: 149

Aichelburg MC. Screening for tuberculosis in HIV-infected patients. 49th Conference of the German Society for Pneumology and Ventilation, Luebeck, Germany, 9-12 April 2008. German Society for Pneumology and Ventilation, 2008: 235